Floatz logo

Therapeutic Allogeneic Lymphocytes

Acute Myeloid Leukemia With FLT3/ITD Mutation

Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityCell therapyPhase 2Dormant
B
56/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
41/ 100
Competitive Position
89/ 100

Competitive context

11 Active assets in the Acute Myeloid Leukemia With FLT3/ITD Mutation cohort.

Asset / SponsorPhaseRating
Gilteritinib
The First Affiliated Hospital of Soochow University
Phase 3BB
Cytosin-Arabinosid
First Affiliated Hospital of Zhejiang University
Phase 3BB
Azacitidine
French Innovative Leukemia Organisation
Phase 2BB
Sorafenib
The First Affiliated Hospital of Soochow University
Phase 3BB
xy0206
Shijiazhuang Yiling Pharmaceutical Co. Ltd
Phase 3BB

View all 23 →

Same molecule, other indications

Therapeutic Allogeneic Lymphocytes is also rated in:

chronic myeloid leukemiaDormant
BBB
Indicative ·
72 / 100
View asset →
Relapsing Chronic Myelogenous LeukemiaDormant
BBB
Indicative ·
72 / 100
View asset →
myelodysplastic/myeloproliferative neoplasmDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →